Non-opioid Analgesics Market Size, Growth, Trends | Report 2022-2030
Non-opioid analgesics have broad applications in treating mild or severe pain, including pain associated with musculoskeletal, surgical, trauma, cancer, or other types of pain. In the last decade, the innovation in the market has been more likely limited to new extended-release formulations and new drug delivery systems. The advancements in delivery systems and new treatments offer improvements in symptom relief. However, effective analgesics with a low risk of intolerance and abuse are still a major unmet need in the market.
Rising restrictions on opioid-based products create lucrative opportunities for the non-opioid drug market. Opioid abuse and addiction, which includes prescription medications & drugs like fentanyl and heroin, is a critical global problem that negatively impacts public health and economic & social wellbeing. In the U.S., approximately 50,000 deaths occurred from opioid-related overdoses in 2021. In addition, according to data from Medicare, in the last decade, opioid prescriptions from oncologists declined by 21% and 23% from other doctors. Similarly, according to the report published by National Cancer Institute in 2021, the same trend had been observed among last-stage cancer patients. This trend is expected to continue during the forecast period, which has created a massive opportunity for space growth.
Analgesic drugs class has been mainly segmented as:
Investment in R&D has led to the development of novel therapeutic options that are highly effective, with lesser side effects. NSAIDs include a group of drugs used in pain, fever, and inflammation due to their analgesic, antipyretic, & anti-inflammatory properties. The space is strategically active with the approval of novel drugs. For instance, Heron Pharma’s ZYNRELEF, an extended-release dual-acting local anesthetic used as a single needle-free application, was approved by the U.S. FDA in May 2021. It is a unique drug for postoperative pain management associated with cancers and other surgeries. It is an essential milestone in ongoing efforts to get ahead of the opioid crisis in the U.S. with preventative measures. Nonetheless, the need for developing a non-opioid-based treatment approach is high, and there remains optimism for developing a novel therapy to treat pain.
Among pain types, neuropathic pain is anticipated to exhibit remunerative growth in the forthcoming years; this is more likely due to the robust product pipeline with major products in Phase II and Phase III development.
Owing to the uncertain opioid regulatory situation, pharma giants are shifting their focus on non-opioid analgesics, companies such as The WIRB-Copernicus Group’s (WCG) acquired Analgesic Solutions, LLC. Major companies operating in the space include AbbVie Inc.; Pfizer, Inc, Lilly; Teva Pharmaceutical Industries Ltd., Viatris Inc., Centrexion Therapeutics, Cara Therapeutics, Medropharm GmbH.
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Non-opioid Analgesics Market
5.1. COVID-19 Landscape: Non-opioid Analgesics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Non-opioid Analgesics Market, By Drug Class
8.1. Non-opioid Analgesics Market, by Drug Class, 2022-2030
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Acetaminophen
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Local Anesthetics
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Non-opioid Analgesics Market, By Pain Type
9.1. Non-opioid Analgesics Market, by Pain Type e, 2022-2030
9.1.1. Post-operative Pain
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Cancer Pain
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Neuropathic Pain
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Non-opioid Analgesics Market, By Route Of Administration
10.1. Non-opioid Analgesics Market, by Route Of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Injectable
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Non-opioid Analgesics Market, By Distribution Channel
11.1. Non-opioid Analgesics Market, by Distribution Channel, 2022-2030
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Non-opioid Analgesics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.1.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. AbbVie Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Pfizer, Inc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Lilly
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Teva Pharmaceutical Industries Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Viatris Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Centrexion Therapeutics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Cara Therapeutics
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Medropharm GmbH
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers